Storytelling vs. Math: How Narratives Shape Biotech Investment Decisions

·38 min·2 clips

An eight-year-old child in hospice with metastatic brain cancer made the investor room go quiet.

1. cc: Life Science Podcast frames a discussion of storytelling versus math in biotech investment decisions with Julian Willard and host Chris. 2. Julian Willard is a board advisor and strategist for biopharma leaders, and Chris runs Life Science Marketing Radio and links the topic to marketing and investor messaging. 3. The episode asks whether biotech capital follows data or narratives, and Julian argues that the industry rewards stories more than science. 4. Julian cites FDA data showing small molecules made up 73% of new drug approvals from 2009 to 2023, or slightly over 400 therapeutics. 5. He compares median development cost at $2.1 billion for small molecules versus $3 billion for biologics, and he says the median development time is about 12.7 years versus 12.5 to 12.6 years. 6. He says small-molecule manufacturing scales with about a 30% unit-cost drop each time production doubles, while biologics require million-dollar bioreactors, cold-chain logistics, and facilities that can cost hundreds of millions of dollars. 7. He adds that annual treatment costs are about $33,000 for small molecules and $92,000 for biologics, which he ties to access and health equity. 8. Julian identifies three distortions: the Inflation Reduction Act gives biologics 13 years of exclusivity and small molecules nine, six out of seven biotech investors are pivoting away from small molecules, and risk-adjusted NPV models overweight peak sales assumptions. 9. He says biotech CEOs enter investor rooms selling stories such as engineered T-cells that turn the immune system into a cancer-fighting machine, instead of 'a kinase pathway' inhibitor. 10. He calls the pitch process a 'shark tank for PhDs' where mouse models, pharmacokinetics, and Monte Carlo simulations matter, but a patient story can still change the room. 11. Julian says narrative becomes a problem when it substitutes for rigor, especially because many biotech CEOs insist they are exceptions to the industry's historical failure rates. 12. He says the industry has created a system where the best storytellers get funded, not necessarily the best science, and he compares investor appetite for big arcs to Los Angeles pitching culture. 13. He argues that sophisticated investors are starting to require 'narrative accountability,' meaning a patient story plus realistic market assumptions, competitive positioning, and risk-adjusted returns. 14. Julian says drug development would work better as a portfolio problem, and he uses BridgeBio as an example of portfolio biotech built on modern portfolio theory. 15. He gives the math example that 10 programs with 20% success rates each can push the probability of at least one success toward 90%, while one 20% program is only one dice roll. 16. He says portfolio biotech needs different incentives, including longer investor horizons, new performance metrics, and leaders who can manage multiple programs instead of one hero asset. 17. On culture, Julian says Europe emphasizes 'us against the world,' while the United States leans toward 'me, me, me' and the drive to be number one. 18. He then uses antibiotics to show market failure, noting that better antibiotics get used less, that a $50,000 drug must compete with $50 amoxicillin, and that BARDA and CARB-X try to decouple development from pure market incentives. 19. The conversation is conversational and fast-moving, with Chris pushing backward through his questions and Julian answering in policy, finance, and investor-language terms. 20. Listeners who follow biotech financing, drug development, and health policy will get the most from it, while people wanting a casual science chat may skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from cc: Life Science Podcast